chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram, Constipation, Groin pain, Muscle spasms
Clinical narrative: Groin pain; Intense cramping; Significant slowdown of GI tract/ constipation/ leaving a trail of stool in intestines; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 12Apr2021 at 09:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient had not reported any other health issues. The patient had no known allergies to medications, food or other products. Concomitant medications included over the counter (OTC) allergy medications, from an unknown date for unknown indication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Apr2021 at 10:00, the patient experienced significant slowdown of GI tract (constipation), leaving a trail of stool in intestines. He also had intense cramping and pain in the groin area which required ER visit to rule out obstruction. He further clarified that he was prescribed with laxative to address. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of significant slowdown of GI tract (constipation), intense cramping and pain in the groin area which included treatment with CT to rule out obstruction, prescribed laxative. The clinical outcome of the events groin pain, intense cramping and significant slowdown of GI tract/ constipation was resolving at the time of report.   No follow-up attempts are needed. No further information is expected. .
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chills, Dizziness, Nausea
Clinical narrative: First 24 hours; waves of dizziness and nausea, short in duration. I felt some pressure on the right side of my chest.  Night 2 woke up with chills.; First 24 hours; waves of dizziness and nausea, short in duration. I felt some pressure on the right side of my chest.  Night 2 woke up with chills.; First 24 hours; waves of dizziness and nausea, short in duration. I felt some pressure on the right side of my chest.  Night 2 woke up with chills.; First 24 hours; waves of dizziness and nausea, short in duration. I felt some pressure on the right side of my chest.  Night 2 woke up with chills.; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included diverticulitis. The patient had known allergies (unspecified). It was reported that two weeks in between the shots the patient was receiving treatment (unspecified) for diverticulitis from an unknown date. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 09:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 09:30, first 24 hours; the patient experienced waves of dizziness and nausea, short in duration. The patient felt some pressure on the right side of her chest. On 10Apr2021, night at 02:00, the patient woke up with chills. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events first 24 hours; waves of dizziness and nausea, short in duration, felt some pressure on the right side of chest, night 02:00 woke up with chills was resolved on an unknown date in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 73.0
Sex: U
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Very mild fatigue? It felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though . . . maybe because the allergen (spike) was more specific?; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old  patient of unknown gender received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8729) via an unspecified route of administration in the arm right on 01Apr2021 at 17:45 (at the age of 73-year-old) as a single dose for COVID-19 immunization. Medical history included chronic fatigue. Concomitant medications were not reported. The patient previously received bacitracin zinc, neomycin sulfate, polymyxin b sulfate( NEOSPORIN) and pneumococcal vaccine(MANUFACTURER UNKNOWN) on an unknown date and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021, the patient experienced very mild fatigue which felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though maybe because the allergen (spike) was more specific. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events very mild fatigue which felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though maybe because the allergen (spike) was more specific was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Malaise
Clinical narrative: not feeling well; This is a spontaneous report from a contactable consumer. A male patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. It was unknown whether the patient receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. On 14Apr2021, the patient experienced not feeling well after his second dose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the event. The clinical outcome of the event not feeling well was not recovered at the time of this report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Left armpit swelling; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the left arm on 11Apr2021 at 12:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not have any allergies to medications, food or other products. Concomitant medication included etonogestrel (NEXPLANON) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the left arm on 21Mar2021 at 12:15 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the patient experienced left armpit swelling that started 48 hours after vaccination. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event left armpit swelling was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site pain
Clinical narrative: sore arm at injection site; tiredness; This is a spontaneous report from a non-contactable consumer, the parent. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 12Apr2021 at 15:30 (at the age of 17-year-old) as a single dose for COVID-19 immunisation. Medical history included covid-19. The patient did not have a history of allergies to medications, food or other products. The patient did not receive any medication within two weeks of vaccination. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 23Mar2021 (at the age of 17-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 13Apr2021 at 11:00, the patient experienced sore arm at injection site and tiredness. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event sore arm at injection site and tiredness was recovered in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Limb discomfort, Vaccination site pain
Clinical narrative: had a lot of pain in the injection site; had trouble moving arm for 2 days.; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 19Mar2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no known allergies. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), vortioxetine hydrobromide (TRINTELLIX, brexpiprazole (REXULTI) and cetirizine (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 21:00, the patient had a lot of pain in the injection site and had trouble moving the arm for 2 days. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events trouble moving the arm was resolved on 21Mar2021 and lot of pain in the injection site was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Pain threshold decreased, Therapeutic response unexpected
Clinical narrative: After each shot, had significant improvement of less pain for 24-48 hours; After each shot, had significant improvement of less pain for 24-48 hours; This is a spontaneous report from a non-contactable consumer, the patient. A 59-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia from an unknown date and unknown if ongoing. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On an unknown date, after each shot, the patient had significant improvement of less pain for 24-48 hours (unexpected therapeutic benefit). The clinical outcome of the event after each shot, had significant improvement of less pain for 24-48 hours was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Gastrointestinal pain, Nausea, Vomiting
Clinical narrative: Lower intestinal distress; Painful lower intestinal distress; Copious vomiting; Nausea with eating; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 07Apr2021 at 13:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Concomitant medications included lamotrigine (LAMICTAL), quetiapine fumarate (SEROQUEL) and meclozine hydrochloride (MECLIZINE), all taken for unspecified indications from unknown dates. The patient previously took keflex and codeine and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 18:00, the patient experienced very painful lower intestinal distress, vomiting for 3-4 hours and continued nausea with eating causing more pain for the next 2 full days. On 13Apr2021, the patient experienced less pain but still had gut unease. The clinical outcome of the events vomiting was resolved on 11Apr2021 and the outcome of nausea was resolved on13Apr2021, while that of painful lower intestinal distress was resolving at the time of this report.  No follow-up attempts are required; information about lot/ batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Sciatica
Clinical narrative: Back pain; Hip pain; Sciatica left side; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm left on 03Apr2021 at 08:30 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included propranolol (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN) and hydrochlorothiazide (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via unspecified route of administration in the left arm on 13Mar2021 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05Apr2021, the patient experienced back pain, hip pain, sciatica left side. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with muscle relaxers and ant inflammatory drugs from an unknown date. The clinical outcome of the events back pain, hip pain, sciatica left side were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia, Vision blurred
Clinical narrative: vision went blurry; arm all the way to hand started to go numb; hand is still numb and tingly.; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the right arm on 13Apr2021 at 10:30 (at the age of 29-years-old), as a single dose for COVID-19 immunisation. Medical history included inflammatory bowel syndrome and known allergy to latex. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 10:30, immediately following the vaccine the patient experienced vision went blurry and arm all the way to hand started to go numb, could barely lift phone and at the time of reporting, arm was feeling somewhat back to normal but hand was still numb and tingly. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event vision went blurry, numb hand and tingly was recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Fatigue, Headache
Clinical narrative: Immediate myalgia's; Hip pain; Chills; Fever (highest was 101.1F); Headache; Extreme fatigue; This is a spontaneous report from a contactable healthcare professional. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via intramuscular route of administration in the left arm on an unknown date in Apr2021 at 07:30 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included bilateral congenital medullary sponge kidney. The patient had no known allergies to medications, food or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 07:45, the patient experienced Immediate myalgia's, hip pain, chills, fever (highest was 101.1F), headache and extreme fatigue. The patient underwent lab tests and procedures, which included body temperature on 12Apr2021 at 07:45 and result was 101.1F (degree Fahrenheit). No therapeutic measures were taken as a result of the reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events immediate myalgia's, hip pain, chills, fever (highest was 101.1F), headache and extreme fatigue was resolved on an unknown date in Apr2021, after the duration of approximately 36 hours.  No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Immediate myalgia's; Hip pain; Chills; Fever (highest was 101.1F); Headache; Extreme fatigue; This is a spontaneous report from a contactable healthcare professional. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via intramuscular route of administration in the left arm on an unknown date in Apr2021 at 07:30 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included bilateral congenital medullary sponge kidney. The patient had no known allergies to medications, food or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 07:45, the patient experienced Immediate myalgia's, hip pain, chills, fever (highest was 101.1F), headache and extreme fatigue. The patient underwent lab tests and procedures, which included body temperature on 12Apr2021 at 07:45 and result was 101.1F (degree Fahrenheit). No therapeutic measures were taken as a result of the reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events immediate myalgia's, hip pain, chills, fever (highest was 101.1F), headache and extreme fatigue was resolved on an unknown date in Apr2021, after the duration of approximately 36 hours.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Contracted Shingles; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 10:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies to medications, food or other products. The patient did not receive any other medications within two weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 16Mar2021 at 15:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 12:00, the patient experienced contracted shingles. The event did result in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles was not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain lower
Clinical narrative: Severe pain in lower right abdomen; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 10Apr2021 at 11:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included pre-diabetes and asthma. The patient was allergic to some antibiotics. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 20Mar2021 at 10:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 20:00, the patient experienced severe pain in lower right abdomen. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event severe pain in lower right abdomen was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Fatigue, Headache, Malaise
Clinical narrative: intense dizziness; mild malaise; fever of 101.5F; headache; extreme fatigue; slept for 20hours; Mild to moderate vaccination site pain; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 09Apr2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high. Patient had no known allergies. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), vortioxetine hydrobromide (TRINTELLIX), brexpiprazole (REXULTI), and cetirizine hydrochloride (CETRIZINE) all from an unknown date for an unspecified indication. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 19Mar2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 13:30, the patient experienced mild to moderate injection site pain. On 11Apr2021, the patient experienced intense dizziness and mild malaise, followed by fever of 101.5 F, headache, and extreme fatigue, slept for 20hours. Two days following had headache and fever of 99.8 F, headache continued through fourth day following. Had a phone call with CDC doctor to allow me to return to work on Monday 12Apr2021 with remaining symptoms. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with TYLENOL. On 11Apr2021, the patient underwent body temperature and the result was 101.5 Degrees Fahrenheit. On 12Apr2021, the patient underwent body temperature and the result was 99.8 Degrees Fahrenheit. The clinical outcome of the events mild to moderate injection site pain, dizziness and mild malaise, followed by fever of 101.5 F, and extreme fatigue, slept for 20 hours was recovered on an unspecified date in Apr2021. While that of headache was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Somnolence, Vaccination site pain
Clinical narrative: intense dizziness; mild malaise; fever of 101.5F; headache; extreme fatigue; slept for 20hours; Mild to moderate vaccination site pain; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 09Apr2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high. Patient had no known allergies. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), vortioxetine hydrobromide (TRINTELLIX), brexpiprazole (REXULTI), and cetirizine hydrochloride (CETRIZINE) all from an unknown date for an unspecified indication. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 19Mar2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 13:30, the patient experienced mild to moderate injection site pain. On 11Apr2021, the patient experienced intense dizziness and mild malaise, followed by fever of 101.5 F, headache, and extreme fatigue, slept for 20hours. Two days following had headache and fever of 99.8 F, headache continued through fourth day following. Had a phone call with CDC doctor to allow me to return to work on Monday 12Apr2021 with remaining symptoms. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with TYLENOL. On 11Apr2021, the patient underwent body temperature and the result was 101.5 Degrees Fahrenheit. On 12Apr2021, the patient underwent body temperature and the result was 99.8 Degrees Fahrenheit. The clinical outcome of the events mild to moderate injection site pain, dizziness and mild malaise, followed by fever of 101.5 F, and extreme fatigue, slept for 20 hours was recovered on an unspecified date in Apr2021. While that of headache was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Head discomfort, Pain in extremity, Tinnitus
Clinical narrative: A few days after receiving the 1st dose I noticed my head felt like it was "humming" but it seems like it is Tinnitus.; A few days after receiving the 1st dose I noticed my head felt like it was "humming" but it seems like it is Tinnitus.; My left arm was sore for 1-2 days but that is all.; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FR8737) via an unspecified route of administration in the arm left on 02Apr2021 at 08:45 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy (sulfa based medications) and COVID-19. Concomitant medications included sertraline hydrochloride (SERTRALINE), atorvastatin (MANUFACTURER UNKNOWN), ascorbic acid, sodium ascorbate (VITAMIN C) and colecalciferol, menaquinone-7 (VITAMIN K2 + D3) for unknown indication from an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021, few days after receiving the 1st dose the patient noticed that his head felt like it was "humming" but it seemed like it was Tinnitus. The patient had no other side effects other than that. The patient left arm was sore for 1-2 days but that was all. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events head felt like it was "humming" but it seemed like it was tinnitus and left arm was sore was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Headache, Illness, Migraine
Clinical narrative: Body aches; Chills; Fever; Dizziness; Migraine; Headache; Nausea; Vomiting; Sick for 3 days; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 10Apr2021 at 09:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included Hashimoto's, an allergy to penicillin and sulfa (sulfonamide). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), quinidine sulfate, dextromethorphan hydrobromide (NUEDEXTA), topiramate (MANUFACTURER UNKNOWN), tizanidine (MANUFACTURER UNKNOWN) and "S"; all from an unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6207) via an unspecified route of administration in the left arm on 20Mar2021 at 13:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 10Apr2021 at 22:00, about 12 hours after the injection, the patient experienced body aches, chills, fever, dizziness, migraine headache, nausea and vomiting and the patient reported that she had "been in bed sick for 3 days" and had finally started to feel better. The patient reported that she had to miss work. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events body aches, chills, fever, dizziness, migraine headache, nausea, vomiting and "been in bed sick for 3 days" was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, Vomiting
Clinical narrative: Body aches; Chills; Fever; Dizziness; Migraine; Headache; Nausea; Vomiting; Sick for 3 days; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 10Apr2021 at 09:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included Hashimoto's, an allergy to penicillin and sulfa (sulfonamide). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), quinidine sulfate, dextromethorphan hydrobromide (NUEDEXTA), topiramate (MANUFACTURER UNKNOWN), tizanidine (MANUFACTURER UNKNOWN) and "S"; all from an unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6207) via an unspecified route of administration in the left arm on 20Mar2021 at 13:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 10Apr2021 at 22:00, about 12 hours after the injection, the patient experienced body aches, chills, fever, dizziness, migraine headache, nausea and vomiting and the patient reported that she had "been in bed sick for 3 days" and had finally started to feel better. The patient reported that she had to miss work. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events body aches, chills, fever, dizziness, migraine headache, nausea, vomiting and "been in bed sick for 3 days" was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Chills, Dry mouth, Headache, Nausea
Clinical narrative: Sore Arm; Achy body; Headache; Neck pain; Back pain; Chills; Fever; Dry mouth; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 13:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not receive any concomitant medication. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 13:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 14:00, the patient experienced sore arm, headache, neck pain, back pain, chills, dry mouth, nausea, achy body and fever. Therapeutic measures were not taken as a result of these events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of sore arm, headache, neck pain, back pain, chills, dry mouth, nausea, achy body and fever was recovering at the time of this report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Neck pain, Pain, Pain in extremity, Pyrexia
Clinical narrative: Sore Arm; Achy body; Headache; Neck pain; Back pain; Chills; Fever; Dry mouth; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 13:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not receive any concomitant medication. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 13:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 14:00, the patient experienced sore arm, headache, neck pain, back pain, chills, dry mouth, nausea, achy body and fever. Therapeutic measures were not taken as a result of these events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of sore arm, headache, neck pain, back pain, chills, dry mouth, nausea, achy body and fever was recovering at the time of this report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Ear discomfort, Tinnitus
Clinical narrative: Right ear plugged and ringing; Right ear ringing; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 14:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included kidney transplant. The patient had no known allergies to food, medication or other product. Patient did not receive any other medication within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 17:30, the patient experienced right ear plugged and ringing. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events right ear plugged and ringing was resolving at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain, Rash papular
Clinical narrative: Rash on left side of back with bumps; Pain where the rash eventually appeared; Chills the day before the rash showed up; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 09Apr2021 at 14:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included heart condition- catecholaminergic polymorphic ventricular tachycardia (CPVT). The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included flecainide (MANUFACTURER UNKNOWN) and nadolol (MANUFACTURER UNKNOWN); both from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 12Mar2021 at 14:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021, the day before the rash showed up, the patient experienced chills. On 13Apr2021, the patient experienced rash on left side of back with bumps and pain where the rash eventually appeared. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, rash on left side of back with bumps and pain where the rash eventually appeared was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Conjunctivitis, Eye discharge, Eye irritation, Eye swelling, Ocular hyperaemia
Clinical narrative: Redness, burning, discharge and swelling to the left eye. Suspected conjunctivitis.; Redness, burning, discharge and swelling to the left eye. Suspected conjunctivitis.; Redness, burning, discharge and swelling to the left eye. Suspected conjunctivitis.; Redness, burning, discharge and swelling to the left eye. Suspected conjunctivitis.; Redness, burning, discharge and swelling to the left eye. Suspected conjunctivitis.; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11Apr2021 at 12:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no known allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 22:00, the patient experienced redness, burning, discharge and swelling to the left eye. The patient suspected conjunctivitis. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events redness, burning, discharge and swelling to the left eye, suspected conjunctivitis was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Tongue discolouration
Clinical narrative: tongue is almost completely white; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 59267-1000-01) via an unspecified route of administration in the left arm on 13Apr2021 at 11:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 06:00, the patient experienced tongue is almost completely white. No therapeutic measures were taken as a result of the reported adverse event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event tongue white was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.